Skip to main
INKT

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics Inc has experienced a significant increase in its stock price, rising over 400% recently compared to a mere 2% increase in the Nasdaq Biotechnology Index, reflecting strong market enthusiasm. The company’s innovative approach to iNKT cell therapies, characterized by scalable and cost-effective manufacturing capabilities and dual mechanisms of action, positions it favorably within the biopharmaceutical landscape. Furthermore, ongoing and upcoming clinical trials—including the agenT-797 Phase 2 gastric trial—are anticipated to attract additional investment and validate the therapeutic potential of its product pipeline.

Bears say

MiNK Therapeutics Inc. faces significant risks that could negatively impact its stock, including the potential emergence of safety signals in ongoing clinical or preclinical programs, which could hinder its therapeutic advancement. The company also risks lower-than-expected efficacy from its clinical trials, greater competition within the market, and potential regulatory challenges affecting its assets. Additionally, there are concerns regarding financing needs amounting to approximately $55 million through 2038, a limited cash runway extending only into mid-2025, and the risk of de-listing if share prices fall below $1.

MiNK Therapeutics (INKT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, MiNK Therapeutics (INKT) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.